Clometacin

Summary

Clometacin (CHEMBL13376) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 357.8 Da · C19H16ClNO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL13376
Name	Clometacin
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	33176
Molecular formula	C19H16ClNO4
Molecular weight	357.8
InChIKey	DGMZLCLHHVYDIS-UHFFFAOYSA-N

SMILES: CC1=C(C2=C(N1CC(=O)O)C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl

IUPAC name: 2-[3-(4-chlorobenzoyl)-6-methoxy-2-methylindol-1-yl]acetic acid

Also known as: C 1656, C-1656, Clometacin, Clometacina, Clometacine, R 3959, R-3959, clometacin, CLOMETACINE, SID144206860, CLOMETACIN

Patent coverage: 479 distinct patent families (2,038 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 2,033 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Prostaglandin-H2 D-isomerase.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 1 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
O09114	6.7	IC50	200	nM	CHEMBL_ACT_377662

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).